Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer

Citation
Borre, Pierre Vanden, Viswanath Gunda, David G. McFadden, Peter M. Sadow, Shohreh Varmeh, Maria Bernasconi, and Sareh Parangi. 2014. “Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.” Oncotarget 5 (12): 3996-4010.

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785929

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Combined BRAF<sup>V600E</sup>- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer

Pierre Vanden Borre<sup>1</sup>, Viswanath Gunda<sup>1</sup>, David G. McFadden<sup>2</sup>, Peter M. Sadow<sup>1</sup>, Shohreh Varmeh<sup>1</sup>, Maria Bernasconi<sup>1</sup> and Sareh Parangi<sup>1</sup>

<sup>1</sup>Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
<sup>2</sup>Thyroid Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts

Correspondence to: Sareh Parangi, email: sparangi@partners.org

Keywords: Thyroid, BRAF, SRC

Received: April 3, 2014  Accepted: June 24, 2014  Published: June 26, 2014

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models of thyroid cancer, however, neither drug induces notable apoptosis. Here we report that the SRC-inhibitor dasatinib further sensitizes BRAF<sup>V600E</sup>-positive thyroid cancer cells to the BRAF<sup>V600E</sup>-inhibitor PLX4720. Combined treatment with PLX4720 and dasatinib synergistically inhibited proliferation and reduced migration in PTC and ATC cells. Whereas PLX4720 did not induce robust apoptosis in thyroid cancer cells, combined treatment with dasatinib induced apoptosis in 4 of 6 lines. In an immunocompetent orthotopic mouse model of ATC, combined PLX4720 and dasatinib treatment significantly reduced tumor volume relative to PLX4720 treatment alone. Immune cell infiltration was increased by PLX4720 treatment and this effect was maintained in mice treated with both PLX4720 and dasatinib. Further, combined treatment significantly increased caspase 3 cleavage <i>in vivo</i> relative to control or either treatment alone. In conclusion, combined PLX4720 and dasatinib treatment induces apoptosis, increases immune cell infiltration and reduces tumor volume in a preclinical model of ATC, suggesting that the combination of these FDA-approved drugs may have potential for the treatment of patients with ATC or refractory PTC.

INTRODUCTION

While traditional treatments of papillary thyroid cancer (PTC), including thyroidectomy, thyroid-stimulating hormone (TSH) suppression, and radioactive iodine (RAI) are highly effective at mitigating disease, patients with advanced PTC or undifferentiated (anaplastic) thyroid cancer (ATC) face poor prognosis and need novel therapeutics. Approximately 45% of PTC and dedifferentiated PTC patients have an activating mutation at amino acid 600 of BRAF (BRAF<sup>V600E</sup>) [1, 2]. To improve outcomes for patients with BRAF<sup>V600E</sup>-positive advanced PTC and ATC, efforts have been focused on inhibiting oncogenic BRAF signaling with targeted therapeutics [1, 3-9]. We have previously shown that BRAF<sup>V600E</sup> plays an important role in the aggressive behavior of thyroid cancer cells <i>in vitro</i> and that treatment with the selective BRAF<sup>V600E</sup>-inhibitor PLX4720 results in impressive decreases in tumor volume and metastasis in an orthotopic mouse model of ATC [5-8, 10]. These findings, combined with data from others, led to a phase II clinical trial (NCT01286753) to evaluate the selective BRAF<sup>V600E</sup>-inhibitor vemurafenib in patients with progressive RAI-refractory BRAF<sup>V600E</sup>-positive PTC. Vemurafenib treatment elicited partial responses in a subset of patients. The overall clinical benefit at 6 months was 58% in tyrosine kinase inhibitor (TKI)-naïve patients and treatment extended progression free survival to 15.6 months [11]. Additionally, in a separate case, a patient with ATC exhibited a response to treatment with...
vemurafenib [12]. Since complete responses have not been achieved, the results encourage further investigation using more effective combinations to target multiple pathways simultaneously.

While the effectiveness of BRAFY600E-inhibition in melanoma has spurred investigation in thyroid cancer, there are important differences between melanoma and thyroid cancer. Nanomolar concentrations of BRAFV600E-inhibitors are sufficient to inhibit proliferation in melanoma cell lines whereas micromolar doses are required for a similar effect in thyroid cancer cell lines [6-8, 13, 14]. Furthermore, unlike melanoma cells, thyroid cancer cells do not undergo apoptosis when treated with BRAFV600E-inhibitors suggesting the persistence of additional signaling pathways that permit or promote survival [5, 6]. In addition, in melanoma, it appears that oncogenic BRAF-signaling may cloak immune antigens present on the cancer cells and that treating with BRAFV600E-inhibitors promotes anti-tumor immune cell infiltration and activity [15-21]. The potential effects of BRAFV600E-inhibitors on the immune response have not been investigated in thyroid cancer because all previous studies using human thyroid cancer cells have used immunocompromised mice and novel genetically engineered mice with BRAF tumors rarely show aggressive behavior [22].

In an effort to enhance the efficacy of BRAFV600E-inhibition in thyroid cancer, we chose to target additional signaling pathways, chiefly SRC signaling. The Src family of kinases consists of 9 members, with c-Src being the most prevalent in human tumors and specifically in thyroid cancer cells [23, 24]. The Src oncogene, recently identified as a driver of thyroid cancer progression and metastasis, is a compelling therapeutic target as it is an important signaling node that modulates varied downstream signaling including the MAPK, PI3K-AKT, FAK, and STAT3 pathways [23, 25-31]. Activated Src forms a complex with focal adhesion kinase (FAK) and, together, these two kinases affect cell motility, invasion, proliferation, survival, anchorage-independent growth and drug resistance [24, 32].

A number of SRC-inhibitors have been developed, including dasatinib (BMS-354825), a multikinase inhibitor that is primarily appreciated as a dual SRC- and ABL-family inhibitor [24, 33]. It is FDA-approved for patients with chronic myelogenous and acute lymphoblastic leukemia and is being pursued for patients with solid tumors [23, 27, 34-42]. In spite of many intriguing preclinical findings, SRC-inhibitors have thus far shown limited clinical effectiveness when used as a single agent for solid tumors [30]. More recently, several groups have demonstrated that dasatinib treatment reduces tumor growth and inhibits metastasis in various mouse models of BRAFWT and BRAFV600E-positive thyroid cancer [23, 27, 31]. SRC signaling has been implicated in both PTC and ATC with increased expression of pathway members correlating with disease progression, metastatic potential and invasion [23-26, 28, 40, 43-47]. Further, evidence from melanoma, including new data from an unbiased screen for genes conferring resistance to mitogen-activated protein kinase (MAPK) pathway inhibition, suggests that SRC and related Src family kinases play a role in resistance to BRAFV600E-inhibition [32, 48]. We believe there is potential to use SRC-inhibitors in combination with BRAFV600E-inhibitors to treat advanced PTC and ATC.

Our study examines the response of genetically defined murine PTC and ATC cell lines to PLX4720, dasatinib and a combination of these drugs in vitro. This approach resonates with the current vision for personalized medicine in which rational therapeutic combinations result in increased efficacy as well as potential for reduced side effects. Additionally, we validate our in vitro data in an immunocompetent orthotopic model of aggressive ATC, permitting analysis of the host immune response to the treatment of tumor growth in the thyroid, an aspect of increasing importance given the potential for emerging immunotherapies.

RESULTS

Dasatinib effectively inhibits SRC signaling, but not MAPK signaling, in a panel of murine BRAFV600E-positive thyroid cancer cell lines

SRC signaling, as evidenced by phosphorylation at tyrosine 416 (pSRC(Y416)), is active in a panel of human and murine PTC and ATC thyroid cancer cell lines harboring BRAFV600E. (Table 1, Fig. 1A). Dasatinib treatment reduces basal SRC signaling in the murine cell lines. Notably, while a complete reduction of pSRC(Y416) is achieved in the murine ATC lines with a dose of 50 nM dasatinib, it is modest in the PTC line, TBP-3868, for which 100 nM dasatinib is required to eliminate pSRC(Y416) (Fig. 1B). Dasatinib treatment does not

Table 1: Panel of murine and human thyroid cancer cell lines

| species | cell line | type | mutations |
|---------|-----------|------|-----------|
| murine  | TBP-3868  | PTC  | $Braf_{V600E/WT}$, p53$^{-/-}$ |
|         | TBP-3743  | ATC  | $Braf_{V600E/WT}$, p53$^{-/-}$ |
|         | TBPt-3403 | ATC  | $Braf_{V600E/WT}$, Pten$^{-/-}$ |
|         | TBPt-3610R| ATC  | $Braf_{V600E/WT}$, Pten$^{-/-}$ |
| human   | BCPAP     | PTC  | $Braf_{V600E/WT}$, p53R248G |
|         | 8505c     | ATC  | $Braf_{V600E/-}$, p53D259Y |

(PTC = Papillary Thyroid Cancer, ATC = Anaplastic Thyroid Cancer)
appreciably effect ERK phosphorylation (pERK(T202/Y204)) at doses lower than 100 nM (Fig. 1B). Given that dasatinib does not reduce pERK(T202/Y204) at 50 nM, we treated the murine cell lines with PLX4720. Treatment of the murine ATC cell lines (TBP-3743, TBPt-3403 and TBPt-3610R) with 1 µM of the BRAF^{V600E}-inhibitor PLX4720 decreases pERK(T202/Y204), however a more complete reduction is achieved with a dose of 10 µM. Surprisingly, The PTC line, TBP-3868, exhibits a resistance to PLX4720 with pERK(T202/Y204) persisting with doses up to 50 µM (Fig. 1C).

Combined treatment with PLX4720 and dasatinib inhibits MAPK and SRC signaling and attenuates the PLX4720-induced augmentation of FAK and AKT phosphorylation in a subset of thyroid cancer cell lines

Combined treatment of the ATC cell lines with both 10 µM PLX4720 and 50 nM dasatinib results in a decrease of both pERK(T202/Y204) and pSRC(Y416), whereas only pSRC(Y416) is reduced in the PLX4720-resistant PTC line, TBP-3868 (Fig. 1D).

Notably, phosphorylation of key signaling proteins,
Dasatinib synergizes with PLX4720 to reduce proliferation in PTC and ATC BRAF<sup>V600E</sup> cell lines

Dasatinib exhibited a modest anti-proliferative effect on the murine BRAF<sup>V600E</sup>-positive cell lines. The IC<sub>50</sub> values were determined to be greater than 100 nM, the upper limit of specificity, for each line (TBPT3868 = 223 nM; TBPT3743 = 238 nM; TBPT3403 = 243 nM; TBPT3610R = 363 nM). Consistent with previous reports, dasatinib treatment with BCPAP exhibited sensitivity (85 nM), while the human ATC line, 8505c, showed resistance to dasatinib (1383 nM) (Fig. 2A-B) [23].

Characteristic of thyroid cancer, the murine and human cell lines exhibited high PLX4720 IC<sub>50</sub> values (≥ 15 μM). For each cell line, however, co-treatment with a fixed ratio of dasatinib shifted the dose response curve and lowered the PLX4720 IC<sub>50</sub> value. The IC<sub>50</sub> values of PLX4720 dropped to less than 10 μM in combination with dasatinib (TBPT3868: 27 μM to 9 μM; TBPT3743: 15 μM to 4 μM; TBPT3403: 25 μM to 7 μM; TBPT3610R: 22 μM to 2 μM). Similarly, the IC<sub>50</sub> value of PLX4720 dropped from 35 μM to 14 μM for 8505c and from 17 μM to 1 μM for BCPAP when combined with dasatinib (Fig. 2C-D).

The combined effect of PLX4720 and dasatinib was formally assessed for synergy by Chou-Talalay analysis [49]. The combination index (CI) for each line was less than 1.0, indicating a synergistic effect between PLX4720 and dasatinib. TBPT3868, which in spite of exhibiting resistance to PLX4720 in terms of the pERK(T202/Y204) inhibition, shows synergy with a CI value of 0.524. A synergistic effect was observed in the ATC lines as well, with CI values of 0.451, 0.567 and 0.069 for TBPT3743, TBPT3403 and TBPT3403, respectively. Among the murine lines, TBPT3610R exhibited the lowest CI value indicating strong synergy (Fig. 2E). Similarly, the human lines exhibited strong synergy between PLX4720 and dasatinib with BCPAP and 8505c both exhibiting CI values less than 0.050 (Fig. 2E).

PLX4720 has a significant but variable effect on the migration of murine BRAF<sup>V600E</sup> anaplastic thyroid cancer cell lines whereas dasatinib reduces >90% of the migratory capacity of all cell lines tested

We previously demonstrated that PLX4720 effectively inhibits the migration of the human ATC line, 8505c [6]. Here we show that the migratory capacity of the murine ATC lines TBPT3743, TBPT3403 and TBPT3610R are significantly reduced by treatment with PLX4720. TBPT3610R is less sensitive to PLX4720 treatment than either TBPT3743 or TBPT3403. While PLX4720 treatment reduces the migration of TBPT3743 and TBPT3403 to 22% and 26%, respectively, the migration of TBPT3610R is reduced to only 63% of DMSO-treated control cells (Fig. 3A). In concordance with the demonstrated resistance to PLX4720-mediated pERK(T202/Y204) inhibition in TBPT3868 cells, PLX4720 treatment does not significantly inhibit the migration of this PTC line. In contrast to the variable anti-migratory responses evoked by PLX4720 treatment, dasatinib treatment strongly inhibits cellular migration in each of the cell lines with the migration of TBPT3868, TBPT3743, TBPT3403 and TBPT3610R being reduced to 4%, 1%, 12% and 3%, respectively, of control treated cells. Interestingly, treatment of the PTEN-deficient lines, TBPT3403 and TBPT3610R, with a combination of PLX4720 and dasatinib induces a further significant reduction of migration relative to treatment with either agent alone (Fig. 3A).

Combined treatment of thyroid cancer cell lines with PLX4720 and dasatinib induces apoptosis

Treatment with PLX4720 did not induce a significant difference in the percentage of annexin-V positive cells for any of the lines tested except for the PTEN-null ATC line, TBPT3403, which showed a modest but significant increase to with 8.9±1.8% expressing annexin-V, exhibited a modest but significant increase relative to DMSO-treated cells (p < 0.05) (Fig. 3B). The other murine lines treated with PLX4720 showed no significant apoptosis (Fig. 3B).

Dasatinib treatment of the murine lines did not induce apoptosis, with the percentage of annexin-V...
positive cells not significantly differing between DMSO- and dasatinib-treated cells (Fig. 3B).

Treatment of two of the ATC lines, TBP-3743 and TBPt-3403, with a combination of dasatinib and PLX4720 induced significantly higher percentages of cells to undergo apoptosis relative to either drug alone. Whereas only 8.3±0.9% of DMSO-treated TBP-3743 cells exhibited annexin-V expression, combined PLX4720 and dasatinib treatment induced 34.0±6.0% of the cells to express annexin-V (p < 0.01) (Fig. 3B). Similarly, a significant increase from 4.2±0.3% to 15.9±0.7% is observed in TBPt-3403 (p < 0.001) (Fig. 3B). In contrast, TBP-3868 and TBPt-3610R lines proved refractory to both single agents and the combined treatment, with only 15.3±0.8% and 12.3±1.5% of cells expressing annexin-V following treatment with a combination of PLX4720 and dasatinib (Fig. 3B).

While neither PLX4720 nor dasatinib were effective at inducing apoptosis in human 8505c ATC cells (2.4±0.1% and 3.0±1.2%, respectively, compared to 2.4±0.5% in vehicle treated cells) the combined treatment increased the amount of apoptosis to 6.3±0.3% of the cells (p < 0.05). The human PTC line, BCPAP, has been previously shown to be sensitive to dasatinib and while control cells exhibited relatively high levels of annexin-V positive cells (12.3±3.6%), treatment with PLX4720 or dasatinib increased the percentage to 24.6±6.5% and 22.7±7.2%, respectively. The combination of PLX4720 and dasatinib significantly increased the amount of apoptosis to 48.9±10.5% (p < 0.05).

The flow cytometry findings are supported by western blot analysis of pro-apoptotic proteins following treatment of the murine thyroid cancer lines with PLX4720 and dasatinib. PARP cleavage and Caspase 3 cleavage are observed in both TBP-3743 and TBPt-3403 when these lines are treated with both PLX4720 and dasatinib (Fig. 3C).

Figure 2: PLX4720 and dasatinib synergistically reduce cellular proliferation in mouse and human PTC and ATC cell lines. A. Cellular proliferation curves for the murine TBP-3868, TBP-3743, TBPt-3403 and TBPt-3610R lines and the human BCPAP and 8505c lines treated with a range of doses of dasatinib (0.1 nM to 100 µM). B. Dasatinib IC\textsubscript{50} values were calculated using GraphPad Prism. C. Proliferation curves for PLX4720 (PLX, 0.1 µM to 100 µM) and PLX4720 plus a fixed ratio dose of dasatinib (PLX+DAS, 200:1). D. PLX4720 IC\textsubscript{50} values were calculated for cells treated with either PLX4720 alone or both PLX4720 and dasatinib at a 200:1 ratio. E. The interaction between PLX4720 and dasatinib synergistically reduces cell mouse and human thyroid cancer cell proliferation as determined by Chou-Talalay analysis. The combination index (CI), calculated using Compusyn, is less than 1.0 for each line tested indicating synergy.
Combined dasatinib and PLX4720 treatment reduces tumor volume in a pre-clinical mouse model of aggressive ATC

To investigate the efficacy of combined PLX4720 and dasatinib treatment in vivo we utilized a newly described immunocompetent model of aggressive thyroid cancer. In this model highly aggressive ATC cells, TBP-3743, transduced with constructs expressing luciferase and green fluorescent protein (GFP) were implanted in the thyroids of B6129SF1/J mice as previously described, which results in rapid tumor progression and local invasive behavior, typically resulting in death of the mouse approximately 14 days post-implantation. This model allows analysis of tumor progression with luciferase imaging and also analysis of immune cell infiltration into the tumor (Fig. 4A) [50]. Six days following implantation, pre-treatment luciferase activity was measured to assess tumor take and progression. Equivalent luciferase activity was detected in the neck region of imaged mice indicating marked and consistent tumor growth (Fig. 4B). Gross examination two weeks post-implantation (one week of treatment) revealed that tumors developed to the left side of the trachea near the site of implantation (Fig. 4C). Fluorescence imaging indicated that the primary tumors were GFP-positive, however luciferase live-imaging, post necropsy GFP-imaging or gross inspection indicated distant metastases to the lung (Fig. 4B-C and data not shown). The average body weight of mice from both the control and the dasatinib treated groups was significantly lower than that of mice from either the PLX4720 or combined treatment groups two weeks post-implantation, following one week of treatment (Fig. 4D). Mice treated with PLX4720, dasatinib or a combination exhibited markedly smaller tumors than control mice two weeks post-implantation (Fig. 4C, E, F).

In addition to palpable tumors in the neck region, the mice implanted with TBP-3743 ATC and fed a control diet exhibited poor body condition, a dramatic loss of body weight and were euthanized two weeks post-implantation. These control mice developed large thyroid tumors with a mean volume 23152 mm³. At two weeks, mice in the dasatinib-treated group exhibited significantly smaller tumors than the control group (123±28 mm³; p < 0.001), however similarly presented with poor body condition, exhibited a dramatic reduction in body weight and were euthanized. Mice fed PLX4720-impregnated chow exhibited tumors with a mean volume of 92±68 mm³ two weeks post-implantation, significantly lower

Figure 3: Combined treatment with PLX4720 and dasatinib reduces cellular migration and induces apoptosis in a subset of PTC and ATC cell lines. A. PLX4720 has a significant but variable effect on the migration of murine ATC whereas dasatinib strongly reduces the migratory capacity of all cell lines tested. Percent migration relative to DMSO-treated control cells for each murine thyroid cancer cell line was determined following treatment for 16 hours with DMSO, 10 μM PLX4720, 50 nM dasatinib or a combination of 10 μM PLX4720 and 50 nM Dasatinib prior to seeding into transwell migration chambers, under continuous treatment, for migration along a serum gradient for an additional 24 hours. B. To determine percent apoptosis relative to DMSO-treated controls, annexin-V expression was determined by FACS analysis of the cell lines treated with DMSO, 10 μM PLX4720, 50 nM dasatinib, or both 10 μM PLX4720 and 50 nM dasatinib for 18 hours. C. Western blot analysis of whole cell lysates from treated cells. Membranes were probed for Caspase 3 and PARP. Beta actin was probed to verify equal protein loading. Both the migration (conducted in duplicate) and the annexin-V expression experiments were independently performed three times and the means are displayed with SEM. Significant differences are denoted by p values < 0.05 as determined by Student’s t-test for the migration assays and by one-way ANOVA followed by Tukey multiple comparison test for the annexin-V analysis.
than the control group ($p < 0.01$). Mice treated with the combination of both dasatinib and PLX4720 developed tumors with mean volumes of $62 \pm 26 \text{ mm}^3$, significantly smaller than the control mice ($p < 0.0001$) (Fig. 4E, F). Though the mean tumor volumes of the PLX4720-treated mice and the mice receiving the combined treatment did not significantly differ from the mean tumor volume of the dasatinib-treated group, mice in these groups maintained body weight and appeared healthy (Fig. 4D).

The PLX4720 and combined treatment groups survived for an additional week before mice of the PLX4720 treatment began to exhibit poor body condition. The average body weight of mice from both groups began to decline in the third week post-implantation and the mice

![Figure 4: Tumor volume is significantly reduced by combined treatment with both PLX4720 and dasatinib.](image)

A. 70 B6129SF1/J mice were each orthotopically implanted with $10^5$ TBP-3743 luciferase- and GFP-expressing ATC cells and randomized into four groups 6 days later to receive control chow, PLX4720 chow, 50 mg/kg dasatinib 5 days a week, or both PLX4720 chow and 50 mg/kg dasatinib. Pre-treatment luciferase activity was assessed 6 days post-implantation and again at 14 days post-implantation. Due to loss of weight, control and dasatinib-treated mice were euthanized 14 days post-implantation and PLX4720- and combination-treated mice were euthanized 21 days post-implantation. B. Tumor development in the neck is evident by pre-treatment luciferase activity in B6129SF1/J mice 6 days following the orthotopic implantation of $10^5$ TBP-3743 ATC cells. Mice were imaged again at 13 days post-implantation following one week of treatment with control chow, PLX4720, dasatinib or a combination of the PLX4720 and dasatinib. C. Histologic sections of tumor sections two weeks post-implantation stained with hematoxylin and eosin and gross morphology at two and three weeks post-implantation. D. Mean mouse body weight for each group was determined 6 days post-implantation at the start of treatment. E. Tumor volume was determined by direct measurement of the tumor. Two weeks post-implantation, the mean volume of tumor in control mice was significantly larger than the mean volume of tumors in mice treated with PLX4720, dasatinib, or a combination of the drugs for one week. F. Individual tumor volumes at two and three weeks post-implantation. Mean and SEM with significance determined by one-way ANOVA followed by Tukey multiple comparison test ($** p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ relative to control at 2 weeks; ^^^^ $p < 0.0001$ relative to PLX at 3 weeks).
were euthanized. Three weeks post-implantation the mean tumor size of the combined treatment group was 118±26 mm$^3$, significantly lower than that of the PLX4720-treated group, which was 29450 mm$^3$ (p < 0.0001). Notably, the mean tumor size did not significantly change in the combined treatment group from two weeks to three weeks post-implantation.

Caspase 3 cleavage was largely undetectable in tumor sections from control mice suggesting a lack of basal apoptosis (0.9±0.35) (Fig. 5A-B). A modest, but significant, increase in caspase 3 cleavage was observed in PLX4720-treated mice (11.6±2.46; p < 0.01), but not in dasatinib-treated mice (4.6±1.09; p > 0.5) two weeks post-implantation (Fig. 5A-B). Combined treatment resulted in a marked induction of caspase 3 cleavage in vivo, significantly increased relative to both control and individually treated mice (32.2±2.94; p < 0.0001) (Fig. 5A-B).

**PLX4720 treatment induces a robust immune response characterized by the infiltration of cytotoxic T cells, B cells and macrophages**

The implantation of the thyroid cancer cells initially derived from B6129SF1/J mice into syngeneic mice permits study of immune responses to tumor growth and treatment. Tumor tissue obtained from mice treated with PLX4720 featured a marked increase in the infiltration of CD8$^+$ T cells relative to tumor tissue obtained from the control group (Fig. 5C). Dasatinib treatment did not noticeably induce CD8$^+$ T cell infiltration beyond what was detected in the control group (Fig. 5C). Abundant CD8$^+$ T cell infiltration was observed in tumors obtained from mice receiving combined treatment, however the degree of infiltration did not markedly differ from that observed in mice treated with PLX4720 alone.

Whereas sections obtained from TBP-3743 control tumors two weeks post-implantation are largely devoid of infiltrating B220$^+$ B cells, with 2±0.7 cells per high-powered field (hpf), abundant infiltration of B220$^+$ B cells is observed in tumors treated with PLX4720, with 22±5.6 B220$^+$ cells/hpf (p < 0.001) (Fig. 5C-D). Dasatinib treatment does not induce a significant increase in B cell infiltration relative to control (6±1.1 B220$^+$ cells/hpf), however tumors treated with both PLX4720 and dasatinib feature 39±5.6 B220$^+$ cells/hpf, significantly more than what is observed in tumors obtained from control (p < 0.0001). The increase in B cell infiltration into tumors treated with both PLX4720 and dasatinib is modestly, but significantly, higher than the increase in tumors treated with PLX4720 alone (p < 0.05).

---

**Figure 5: PLX4720 and combined treatment with dasatinib induces caspase 3 cleavage and an immune response characterized by T cell, B cell and macrophage/monocyte infiltration.**

A. Tumor sections obtained from each group two weeks post-implantation were probed for cleaved caspase 3. B. Cells staining positive for cleaved caspase 3 were counted in 10 high powered fields (hpf). Mean and SEM with significance determined by one-way ANOVA followed by Tukey multiple comparison test (** p < 0.005; **** p < 0.0001, n.s. not significant). C. Tumor sections obtained from each group two weeks post-implantation were probed for CD8, B220 and F4/80. D. B220-positive cells were counted in 10 hpf. Mean and SEM with significance determined by one-way ANOVA followed by Tukey multiple comparison test (* p < 0.05, ** p < 0.005; **** p < 0.0001, n.s. not significant).
The response of innate immune cells was assessed by probing sections of tumor with a marker of monocytes and macrophages, F4/80. The pattern of infiltration of F4/80+ cells with regard to treatment was similar to the pattern of CD8+ infiltration. Control TBP-3743 tumors were largely devoid of F4/80+ cells whereas tumors from PLX4720-treated mice exhibited marked infiltration. Few F4/80+ cells are observed dasatinib-treated tumors. Tumors obtained from mice receiving combined treatment feature robust infiltration of F4/80+ cells, again, similar to the response observed with PLX4720 treatment alone (Fig. 5C).

**DISCUSSION**

Targeted inhibition of oncogenic signaling is emerging as a viable approach for treating thyroid cancer that is refractory to traditional therapies. As in melanoma, the inhibition of oncogenic BRAF has been a major focus of these efforts in thyroid cancer, however the importance of additional pathways has been recognized. Here we investigate the efficacy of the rational combination of FDA-approved inhibitors of oncogenic BRAF and SRC. In addition, our use of a novel immunocompetent orthotopic murine model permits the analysis of the host immune response to thyroid cancer and treatment.

Our data demonstrate that the combined treatment of BRAF mutated thyroid cancer cells with the BRAFV600E-inhibitor PLX4720 and the SRC-inhibitor dasatinib results in a synergistic increase in the anti-proliferative and apoptotic responses *in vitro*. Further, combined treatment with these inhibitors results in a robust cytotoxic response and decreased tumor volume in a preclinical model of aggressive BRAFV600E-positive ATC. Tumor shrinkage is accompanied by a dramatic host immune response, predominantly driven by PLX4720 treatment and important given the potential for recent innovative immunotherapeutic approaches.

Our lab previously demonstrated that the inhibition of oncogenic BRAF results in dramatic tumor reduction in a model of human ATC and several other groups have shown that dasatinib treatment effectively reduces tumor growth in mice implanted with human BRAFV600E-positive thyroid cancer cells [6,8,23,31]. Of the murine lines examined *in vitro*, we selected the most aggressive murine ATC line, TBP-3743, for implantation and investigation in our immunocompetent model. In addition to harboring oncogenic BRAF, TBP-3743 is p53-null and rapidly forms tumors with locally aggressive features [50]. The control animals in the current study recapitulated our previous observations and developed tumors that lead to dramatic weight loss and death two weeks post-implantation. PLX4720 treatment resulted in a significant reduction of tumor size relative to control and extended survival beyond two weeks. Similarly, dasatinib treatment significantly reduced tumor volume however did not extend survival beyond that of control, as the animals treated with dasatinib alone lost weight and became moribund. Dasatinib is metabolized rapidly in humans, with a plasma half-life less than four hours, and it is possible that with appropriate dosing, perhaps by increasing the frequency of doses, the overall efficacy of dasatinib could be augmented [51]. Most importantly, while PLX4720 significantly reduced tumor volume in this model and permitted survival out to three weeks, the combination of PLX4720 and dasatinib resulted in both the greatest reduction in tumor volume and an increase in apoptotic cells.

Both positives and negative aspects are associated with the use of such an aggressive model. A shortcoming of our *in vivo* model is the lack of metastatic progression, putatively due to the rapidity of tumor growth and mortality. Our laboratory has previously demonstrated that PLX4720 treatment effectively blocks distant metastasis in an immunodeficient orthotopic model of ATC utilizing the human line 8505c [6-8]. Similarly, dasatinib inhibited distant metastasis when a human PTC line, BCPAP, was intracardially injected [23]. It is possible that metastases could develop in the model presented here if either fewer cells are implanted or, alternatively, an approach involving intracardial or tail vein injection is used [23,50,52]. As executed, while metastases do not form, the model is a stringent test for the efficacy of the treatments, as sizeable tumors develop six days post-implantation when the drugs are first administered [23,50,52].

Our experimental design permitted analysis of the immune response to tumorigenesis and treatment. Beyond suppressing tumor growth and inducing apoptosis, the inhibition of oncogenic BRAF evoked an immune-stimulatory effect in mice implanted with TBP-3743. PLX4720 treatment of immunocompetent mice induced the infiltration of CD8+ T cells, B cells and macrophages into the TBP-3743-derived tumor. This observation is consistent with work in melanoma that has demonstrated that BRAFV600E-inhibition stimulates the expression of tumor antigens, induces T cell infiltration and enhances the efficacy of infiltrating T cells [15-21]. Dasatinib treatment did not qualitatively induce CD8+ or macrophage infiltration relative to control and the increase in B cell infiltration was not significant, suggesting the increases observed in the tumors treated with both PLX4720 and dasatinib are largely due to PLX4720 treatment. While BRAFV600E-inhibition has been previously shown to increase tumor infiltrating lymphocytes, it has also been shown to induce the expression of T cell exhaustion markers including PD-L1, TIM3 and PD1 in melanoma patients [53]. It will be of interest to further characterize the T cell response to BRAFV600E-inhibition to determine if combined treatment with immune checkpoint inhibitors will be of benefit in thyroid cancer.

Our *in vivo* findings built on observations *in vitro* which show the combination of PLX4720 and dasatinib
to synergistically inhibit proliferation, reduce migration and induce apoptosis. The combined treatment of either murine or human lines with PLX4720 and dasatinib results in a synergistic shifting of the dose response. Synergy is particularly important as it may permit lower doses of PLX4720 to be used, potentially translating to a benefit in the clinic by reducing side effects associated with BRAF\textsuperscript{V600E}-inhibition including squamous cell carcinoma [54-56].

Among the cell lines tested, the human ATC line 8505c exhibited resistance to dasatinib, yet synergy was observed with combined treatment. Dasatinib has a wide kinase profile at higher doses and in addition to SRC, dasatinib targets a number of important protein kinases including other SRC family kinases, ABL, KIT, EPH receptors, EGFR, PDGFR\textalpha and MAPK proteins including BRAF, CRAF and MEK1 [57]. High doses of dasatinib (100 nM – 2.5 µM) reduced ERK phosphorylation in the murine cell lines suggesting that the anti-proliferative effect of dasatinib treatment may be due, at least in part, to the inhibition of the MAPK pathway. 8505c exhibits the greatest resistance to dasatinib in terms of proliferation (IC\textsubscript{50} = 1383 nM) and expresses low basal SRC activity relative to the other lines tested, suggesting that the reduced proliferation of 8505c cells treated with high doses of dasatinib (e.g. > 1000 nM) alone may be a result of the direct inhibition of BRAF and/or MEK1 by dasatinib. Further this may also suggest the importance of the higher SRC activity observed in the other lines, all of which showed sensitivity to dasatinib at lower doses.

The inhibition of additional, non-SRC, targets by dasatinib may be particularly relevant following Braf\textsuperscript{V600E}-inhibition that leads to a release of negative feedback and the consequent activation of various signaling proteins by kinome reprogramming [13, 58, 59]. The synergy between dasatinib and PLX4720 could potentially be a result of PLX4720-mediated MAPK-inhibition coupled with dasatinib-mediated SRC-inhibition and dasatinib-mediated inhibition of other protein kinases activated by the loss of MAPK-mediated negative feedback.

TBP-3868 is unique among the lines examined in that ERK phosphorylation is maintained in spite of PLX4720 treatment. BRAF\textsuperscript{V600E} signals as a monomer and independently of upstream Ras activity. In the context of wildtype RAF (BRAF or CRAF) and high Ras activity, BRAF\textsuperscript{V600E}-inhibition may “paradoxically” enhance MAPK activity [60, 61]. TBP-3868 exhibits high basal Ras activity relative to the PLX4720 sensitive line, TBP-3743 suggesting that the resistance to BRAF\textsuperscript{V600E}-inhibition in TBP-3868 may be attributed to Ras-dependent transactivation of RAF dimers. Though we do not observe increased ERK phosphorylation following PLX4720 treatment of TBP-3868 cells, ERK phosphorylation is maintained. Treatment of the PLX4720-sensitive line, TBP-3743, with PLX4720 reduces ERK phosphorylation and induces Ras activity. We did not observe increased pSRC(Y416) in response to PLX4720 treatment, however pFAK(Y861) and pAKT(S473) were elevated, suggesting that BRAF\textsuperscript{V600E}-inhibition influences upstream signaling. While increased Ras, FAK and AKT activation following MAPK pathway inhibition is consistent with a release of negative feedback and consequent kinome reprogramming, it is interesting to note that both FAK and Ras are activated by PLX4720 treatment of TBP-3868 in the absence of ERK dephosphorylation. Either, a slight reduction of pERK, imperceptible by western blot analysis, is sufficient for a release of negative feedback or the increased Ras activity is induced by another mechanism. Though SRC may modulate Ras activity via the Ras-GTPase Son-of-Sevenless (SOS), combined treatment with dasatinib does not have an appreciable effect on PLX4720-induced Ras activity in TBP-3743 and only a modest effect on Ras activity in TBP-3868.

PLX4720 is a potent inhibitor of migration, significantly decreasing cellular migration and invasion of human BRAF\textsuperscript{V600E}-positive thyroid cancer lines \textit{in vitro} [6]. In spite of this, though significant, the anti-migratory effect of PLX4720 is variable and incomplete in the murine lines. Dasatinib treatment however nearly completely reduced the migratory capacity of all the murine lines examined. Interestingly, while there was no further anti-migratory benefit of combined treatment of the PTEN-intact lines, a modest but significant reduction was observed in the PTEN-null treated with both PLX4720 and dasatinib relative to treatment with dasatinib alone suggesting that the loss of PTEN confers a more migratory phenotype in these thyroid cancer cell lines.

Combined PLX4720 and dasatinib treatment induced apoptosis in a subset of the thyroid cancer lines examined. Beyond modest inductions, neither PLX4720 nor dasatinib triggered robust apoptosis above baseline when used alone but combined treatment with PLX4720 and dasatinib induced significant apoptosis in TBP-3743, TBPt-3403 and in the two human lines tested, 8505c and BCPAP. Though a cytotoxic response to therapy could not be fully predicted based on genotype, differences between the drug response of the PTEN-intact and -null lines did manifest. While apoptosis was induce by combined treatment of the PTEN-intact lines (TBP-3743, 8505c and BCPAP) with the exception of TBP-3868 which is resistant to PLX4720-mediated reduction of pERK, the PTEN-null line TBPt-3610R did not exhibit a cytotoxic response following combined treatment. And though the PTEN-null line TBPt-3403 exhibited a significant increase in apoptosis, it was modest compared to the induction observed in the p53-null line TBP-3743. Dasatinib treatment of TBP-3743 cells reduced pAKT levels, perhaps permitting apoptosis, whereas the high basal pAKT levels in the PTEN-null cells were unaffected by dasatinib treatment, suggesting that the loss of PTEN and the concomitant increase of AKT signaling may be a factor.
influencing resistance to apoptosis following \( \text{BRAF}^{\text{V600E}} \) inhibition as has been demonstrated in melanoma [62].

In summary, the \( \text{BRAF}^{\text{V600E}} \)-inhibitor PLX4720 and the SRC-inhibitor dasatinib synergize to inhibit proliferation, reduce cellular migration and induce apoptosis in a variety of \( \text{BRAF}^{\text{V600E}} \)-positive PTC and ATC cell lines. The reduction of tumor growth characterized by increased apoptosis and immune cell infiltration in a preclinical model of ATC further suggest that this therapeutic combination holds promise for patients with aggressive thyroid cancer and may further benefit from additional combination with emerging immunotherapies. Going forward it will be important to determine the effect of combined treatment on metastasized thyroid cancer and over an extended period of time, to elucidate the genetic or epigenetic contributions leading to variable responses to treatment and to further characterize the immune response to treatment. Taken as a whole, these findings now show high potential for clinical impact to patients with \( \text{BRAF}^{\text{V600E}} \)-positive anaplastic or refractory papillary thyroid cancer, who currently lack an effective treatment.

**METHODS**

**Cell Culture and in vitro Drug Treatment**

Murine cell lines (TBP-3868, TBP-3743, TBPt-3403 and TBPt-3610R) were previously derived from autochthonous tumors arising in “TBP” mice with thyroid-specific expression of \( \text{Braf}^{\text{V600E}} \) and thyroid-specific knockout of \( p53 \) (TPOCreER; \( \text{Braf}^{\text{V600E}} \text{tm1Mmcm/WT}; \text{Trp53}^{\text{tm1Brn/tm1Brn}} \) or “TBPT” mice with thyroid-specific expression of \( \text{Braf}^{\text{V600E}} \) and thyroid-specific knockout of \( \text{Pten} \) (TPOCreER; \( \text{Braf}^{\text{V600E}} \text{tm1Mmcm/WT}; \text{Pten}^{\text{tm1Hwu/tm1Hwu}} \) as described (Table 1) [50] (McFadden et al, manuscript submitted). For orthotopic implantation TBP-3743, were previously lentivirally transduced to produce cells expressing both luciferase and green fluorescent protein (GFP) [50]. The murine lines, along with the human ATC line, 8505c (Deutsche Sammlung von Mikroorganismen und Zellkulturen), and the human PTC line, BCPAP (previously provided by Dr. G. Damante of the University of Udine, Italy), were maintained in culture using Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and penicillin/streptomycin.

For *in vitro* treatments, PLX4720 (Plexxikon Inc., Berkeley CA) and dasatinib (TSZChem-BIOTANG, Lexington, MA) were each dissolved in dimethyl sulfoxide (DMSO) to respectively yield 10 mM and 5 mM stock solutions. Cells were treated with either 0.1% dimethyl sulfoxide (DMSO), PLX4720 at concentrations ranging from 0.1 \( \mu \text{M} \) to 100 \( \mu \text{M} \), 50nM dasatinib, or a combination of both 10 \( \mu \text{M} \) PLX4720 and 50 nM dasatinib overnight, unless otherwise specified.

**Western Blot Analysis**

Whole cell lysates (WCLs) were probed with antibodies against phosphor-SRC(Y416), SRC, phospho-FAK(861), FAK, ERK, phospho-ERK(T202/Y404), AKT, phospho-AKT(S473), PTEN, Caspase 3, PARP and tubulin (Cell Signaling Technologies, Beverly, MA) following separation by SDS-PAGE and transfer to a nitrocellulose membrane.

**Ras activation assay**

GTP-bound Ras was detected in WCLs obtained from TBP-3743 and TBP-3868 cells treated as above with DMSO, 10 \( \mu \text{M} \) PLX4720, 50 nM dasatinib or a combination of both PLX4720 and dasatinib for 24 hours. We used the active Ras detection kit (Cell Signaling Technologies, Beverly, MA) and followed the manufacturer’s instructions. In brief, GST-bound CRAF (RAF1) Ras binding domain (RBD) was incubated with 500 \( \mu \text{g} \) WCLs. Following sample preparation, input whole cell lysates and pull down samples were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed for with antibodies against RAS, pERK(T202/Y404), ERK and tubulin.

**Proliferation Assay and Chou-Talalay Synergy Analysis**

Cellular proliferation was assessed with CellTiter Aqueous One solution (Promega, Madison, WI). Murine cell lines were plated in triplicate in 96 well plates with 2500 cells per well and treated with varying doses of dasatinib, PLX4720 or a combination for 72 hours. Each experiment was conducted in triplicate and independently repeated three times. Prism (GraphPad Software, San Diego, CA) was used to calculate nonlinear fit of growth curves and determination of \( IC_{50} \). Synergy was formally assessed by Chou-Talalay analysis and the combination index (CI) was calculated using CalcuSyn (Biosoft, Cambridge, UK).

**Annexin-V Apoptosis Analysis**

Cultured cells were collected, washed in PBS, incubated with Annexin-V Alexa Fluor 647 conjugate in Annexin-V binding buffer (Invitrogen, Life Technologies, Grand Island NY) and stained with propidium iodide (Sigma, St. Louis, MO) for analysis on a BD Sorp 8 Laser LSR II (BD Biosciences, San Jose, CA). Flow cytometry data was analyzed using FlowJo (Tree Star Inc., Ashland, OR). Experiments were repeated independently three
times and statistical comparison was made with one-way analysis of variance (ANOVA) followed by the Tukey post hoc multiple comparison test. Statistical significance was determined by p-values < 0.05.

Migration Assay

Migration assays were performed using 2.5x10⁵ cells per well. Cells were treated in DMEM containing 0.1% FCS for 18 hours prior to seeding into 8 μm transwell inserts containing DMEM with 0.1% FCS in the upper well and DMEM with 5% FCS in the lower well. Cells were incubated at 37°C and 5% CO₂ for 24 hours prior to methanol fixation, Giemsa staining and counting. Three independent experiments were conducted in duplicate and results were analyzed with Student’s t-test following normalization of the DMSO-treated samples. p-values < 0.05 were considered significant.

Orthotopic Implantation and in vivo Drug Treatment

All animal work was done at Massachusetts General Hospital (Harvard Medical School) in accordance with federal, local, and institutional guidelines. TBP-3743 cells expressing luciferase and GFP were implanted in the thyroids of B6129SF1/J syngeneic mice as previously described [50, 63]. In brief, thyroids of age-matched female B6129SF1/J mice were unilaterally implanted with 10⁵ TBP-3743-lucGFP cells suspended in 10 l serum-free DMEM. The right thyroid was not manipulated and was used as an internal control. Mice were randomized into four groups 6 days post-implantation and placed on respective treatment regimens. The control group received a control diet (Research Diets, Inc.) (n=9), the PLX4720-treated group received PLX4720-impregnated chow (417 mg/kg, Research Diets, Inc.) ad libitum (n=20), the dasatinib-treated mice received control diet and were orally gavaged with 50 mg/kg dasatinib (Toronto Research Chemicals, Toronto, Ontario, Canada) in 80 mM sodium citrate five days per week (n=20), and the combined treatment group received both PLX4720-impregnated chow ad libitum and were orally gavaged with 50 mg/kg dasatinib five days per week (n=20). Mice were weighed every other day. Mice were sacrificed and tumor volume was calculated as (π/6) × length × width × height [64]. Prism (GraphPad Software, San Diego, CA) was utilized for statistical analysis of tumor volumes. Statistical difference was determined with ANOVA followed by the Tukey post hoc multiple comparison test and p-values < 0.05 were considered significant.

Bioluminescence Imaging

Mice were anesthetized with CO₂ and injected with luciferin for the detection of luciferase activity using an IVIS Imaging System 100 (Perkin Elmer, Waltham, MA) one week post-implantation prior to treatment and two weeks post-implantation after one week of treatment.

Histological and Immunohistochemical Analysis

Tissue specimens were fixed with 10% buffered formalin phosphate and embedded in paraffin blocks. Hematoxylin and eosin stained sections were evaluated by an endocrine pathologist (P.S.) and processed for immunohistochemical analysis (IHC) as previously described [8]. IHC was performed using CD8 (Leica Microsystems Inc., Buffalo Grove, IL), B220 (BD Pharmingen, San Jose, CA), F4/80 (AbD Serotec, Raleigh, NC) antibodies. Stained and IHC tissue sections were photographed using an Olympus BX41 microscope and the Olympus Q COLOR 5 photo camera (Olympus Corp., Lake Success, NY). Caspase 3 cleavage was quantified in tumor sections by manually counting positive cells in ten 400X fields for each sample.

FUNDING

Supported by National Institute of Health Grants R01CA149738 (to SP) and F32CA177282 (to PVB). Sareh Parangi is additionally funded through the American College of Surgeons and the American Thyroid Association.

CONFLICTS OF INTEREST

All authors certify that they have no competing financial interests pertaining to any of the data or statements given in this article.

ACKNOWLEDGEMENTS

We thank David Dombkowski of the MGH Flow Cytometry Core, Derrick Jeon of the Center for Systems Biology at MGH for assistance with live imaging and Patricia Della Pelle of the Department of Pathology at MGH for histology and immunohistochemistry. We would also like to thank David Zurakowski of Children’s Hospital for his insight into the statistical design of the in vivo work. We also extend gratitude to Gideon Bollag and Paul Lin (Plexxikon) for providing PLX4720.
REFERENCES

1. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28(7):742-762.

2. Bhajee F and Nikiforov YE. Molecular analysis of thyroid tumors. Endocr Pathol. 2011; 22(3):126-133.

3. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008; 105(8):3041-3046.

4. Nikiforov YE and Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011; 7(10):569-580.

5. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010; 107(23):10649-10654.

6. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA and Parangi S. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011; 16(3):296-309.

7. Nehs MA, Nagarkatti S, Nucera C, Hodin RA and Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery. 2010; 148(6):1154-1162.

8. Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA and Parangi S. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012; 153(2):985-994.

9. Xing J, Liu R, Xing M and Trink B. The BRAFVT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun. 2011; 404(4):958-962.

10. Nucera C, Goldfarb M, Hodin R and Parangi S. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta. 2009; 1795(2):152-161.

11. Brose M. An Open-Label, Multi-Center Phase 2 Study of the BRAF Inhibitor Vemurafenib in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine (NCT01286753, NO25350) [abstract]. 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress. 2013.

12. Rosove MH, Peddi PF and Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013; 368(7):684-685.

13. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N and Fagin JA. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013; 3(5):520-533.

14. Salerno P, De Falco V, Tamburrino A, Nanni TC, Vecchio G, Schweppe RE, Bollag G, Santoro M and Salvatore G. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010; 95(1):450-455.

15. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizee G, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19(5):1225-1231.

16. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen QJ, Li HS, Watowich SS, Yang Y, Tompers Frederck D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013; 19(2):393-403.

17. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H and Wargo JA. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010; 70(13):5213-5219.

18. Saponita B, Hill CE and Pollack BP. Vemurafenib induces MHC induction in BRAF homozygous melanoma cells. Oncoimmunology. 2013; 2(12):e22890.

19. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P and Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012; 18(5):1386-1394.

20. Donia M, Fagone P, Nicoletti F, Andersen RS, Hodgall E, Straten PT, Andersen MH and Svane IM. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology. 2012; 1(9):1476-1483.

21. Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Joseph RW, Bernatchez C, Ekmeckcioglu S, Grimm E, Radvanyi LG, Davis RE, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012; 18(19):5329-5340.

22. Antonello ZA and Nucera C. Orthotopic mouse models for...
the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF or wild-type BRAF. Oncogene. 2013.

23. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR and Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012; 18(13):3580-3591.

24. Kim LC, Song L and Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009; 6(10):587-595.

25. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL and Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009; 94(6):2199-2203.

26. Kim WG, Guigon CJ, Fozzatti L, Park JW, Lu C, Willingham MC and Cheng SY. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer. Clin Cancer Res. 2012; 18(5):1281-1290.

27. Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, Ngan BD, Braunstein GD and Koeffler HP. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncol Lett. 2012; 3(4):807-815.

28. Cho NL, Lin CI, Du J, Whang EE, Ito H, Moore FD, Jr. and Ruan DT. Global tyrosine kinase profiling of human thyroid tumors identifies Src as a promising target for invasive cancers. Biochem Biophys Res Commun. 2012; 421(3):508-513.

29. Caccia D, Micciche F, Cassinelli G, Mondellini P, Casalini P and Bongarzone I. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Mol Cancer. 2010; 9:278.

30. Zhang S and Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012; 33(3):122-128.

31. Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Galiix GE, Lai SY and Clayman GL. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2013.

32. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE and Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 2013; 504(7478):138-142.

33. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ and Heinrich MC. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006; 66(1):473-481.

34. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM and Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(30):4609-4615.

35. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A and Szol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011; 117(10):2202-2208.

36. Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S and Blackwell KL. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res. 2011; 17(18):6061-6070.

37. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007; 29(11):2289-2308.

38. Finn RS, Derer G, Gitterer C, Wilson CA, Glaspy P, Tchekmedyan N and Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type”triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007; 105(3):319-326.

39. Aleshin A and Finn RS. SRC: a century of science brought to the clinic. Neoplasia. 2010; 12(8):599-607.

40. Rice L, Lepler S, Pampo C and Siemann DM. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clin Exp Metastasis. 2012; 29(2):133-142.

41. Park BJ, Whichard ZL and Corey SJ. Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy. Cancer Lett. 2012; 320(1):104-110.

42. Mayer EL and Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res. 2010; 16(14):3526-3532.

43. Hiscox S, Morgan L, Green TP, Barrow D, Gee J and Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 2006; 97(3):263-274.

44. Mitra SK and Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006; 18(5):516-523.

45. Walsh C, Tanjoni I, Uryu S, Tomar A, Nam J, Luo H, Phillips A, Patel N, Kwock C, McMahon G, Stupack DG and Schlaepfer DD. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther. 2010; 9(10):778-790.

46. Michailidi C, Giaginis C, Stolakis V, Alexandrou P, Klijanienko J, Dalladetsima I, Chatzizacharias N, Tsouroufis G and Theocharis S. Evaluation of FAK and Src...
expression in human benign and malignant thyroid lesions. Pathol Oncol Res. 2010; 16(4):497-507.

47. Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ and Cance WG. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996; 3(1):100-105.

48. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaţ D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C and Marais R. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 2013; 3(2):158-167.

49. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-446.

50. Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi MJ, Jacks T and Parangi S. The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAF<sup>V600E</sup>-Positive Papillary and Anaplastic Thyroid Carcinoma. Thyroid. 2013.

51. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacors JI, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A, Jr, Blackwood-Chirchir A, Humphreys WG, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008; 36(7):1357-1364.

52. Zhang L, Gaskin K, Yu Z, Xiong Y, Merino M and Kebebew E. An in vivo Mouse Model of Human Thyroid Cancer Metastasis. Thyroid. 2013.

53. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J and Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013; 19(3):598-609.

54. Mays R, Curry J, Kim K, Tsai K, Arora A, Khan F, Ramirez-Fort M and Ciurea A. Eruptive squamous cell carcinomas after vemurafenib therapy. J Cutan Med Surg. 2013; 17(6):419-422.

55. Gibney GT, Messina JL, Fedorenko IV, Sondak VK and Smalley KS. Paradoxical oncogenesis–the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013; 10(7):390-399.

56. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013; 23(10):1277-1283.

57. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoon R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26(1):127-132.

58. Johnson GL, Stuhlmiller T, Ang J, Zawistowski J and Graves L. Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer. Clin Cancer Res. 2014.

59. Lito P, Rosen N and Solit DB. Tumor adaptation and resistance to RAF inhibitors. Nat Med. 2013; 19(11):1401-1409.

60. Poulikakos PI, Zhang C, Bollag G, Shokat KM and Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464(7287):427-430.

61. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA and Rosen N. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012; 22(5):668-682.

62. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL and Smalley KS. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011; 71(7):2750-2760.

63. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V and Parangi S. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 2009; 19(10):1077-1084.

64. Tomayko MM and Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3):148-154.